Crohn's DiseaseCAPENCT02130362
A Non-Interventional Clinical Study to Evaluate Long-Term Safety and Effectiveness of HUMIRA (Adalimumab) in Pediatric Patients With Moderately to Severely Active Crohn's Disease (CD)
An observational study of Crohn's Disease, run by AbbVie at 148 sites in 22 countries.
Trial summary
This is a registry study to evaluate the long-term safety and effectiveness of adalimumab in pediatric patients with moderately to severely active CD who are treated as recommended in the local product label. Read more about this study
- Who is it for?
- Ages 6 to 17 years
- Conditions the study is for
- Crohn's Disease
- How many people
- 1,446 participants
- Where
- 148 sitesin 22 countries
- Study dates
- 28 Aug 2014to Nov 2030
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 6 to 17 years
- All sexes
- No healthy volunteers
- Child
Study population: Pediatric patients with moderately to severely active Crohn's Disease (CD) who have been prescribed HUMIRA according to the local label and pediatric patients being prescribed and treated with IMM (azathioprine, 6-mercaptopurine, or methotrexate). Patients being prescribed and treated with immunosuppressant therapy with no concurrent biologic use will be enrolled as a reference group.
Who may be able to join
- For a patient enrolling into the HUMIRA treatment group; A pediatric patient between the ages of 6 and 17 years inclusive at the time of enrollment, diagnosed with moderately to severely active CD who has been prescribed Humira therapy according to the routine clinical practice.
- For a patient enrolling into the immunosuppressant therapy treatment group; A pediatric patient between the ages of 6 and 17 years inclusive at the time of enrollment, diagnosed with moderately to severely active CD who has been prescribed azathioprine, 6-mercaptopurine or methotrexate.
- Parent or guardian; or patient (if 18 years of age or older at enrollment and rolling over from an AbbVie-sponsored investigational Pediatric CD investigation trial) has voluntarily signed and dated an Authorization for Use/Disclosure of Data (AUDD)/informed consent form (ICF) after the nature of the registry has been explained and the patient, patient's parent or legal guardian has had the opportunity to ask questions.
Who cannot join
- Patients should not be enrolled into the registry if they are currently being treated with any investigational agents or are receiving any investigational procedures.
- Patients should not be enrolled into the immunosuppressant therapy treatment group if they require ongoing treatment with approved biologic agents including HUMIRA.
Trial locations and contacts
148 sites in 22 countries.
148 sites in 22 countries
United States45 sites
Winship Cancer Institute of Emory University /ID# 144274
Atlanta, Georgia, 30322
Children's Ctr Digestive, US /ID# 144625
Atlanta, Georgia, 30342
Children's Hospital Colorado - Aurora /ID# 137261
Aurora, Colorado, 80045
Univ Alabama, Birmingham CCC /ID# 146060
Birmingham, Alabama, 35294-3300
Tufts Medical Center /ID# 143581
Boston, Massachusetts, 02111-1552
Massachusetts General Hospital /ID# 141552
Boston, Massachusetts, 02114
Boston Children's Hospital /ID# 164102
Boston, Massachusetts, 02115
Women and Childrens Hosp /ID# 143778
Buffalo, New York, 14222
University Of Vermont Medical /ID# 137263
Burlington, Vermont, 05405
Univ NC Chapel Hill /ID# 137236
Chapel Hill, North Carolina, 27514-4220
Duplicate_Medical University of South Carolina /ID# 144473
Charleston, South Carolina, 29425
Children's Medical Center /ID# 149256
Dallas, Texas, 75235
Geisinger Medical Center /ID# 149910
Danville, Pennsylvania, 17822
Duke Cancer Center /ID# 137268
Durham, North Carolina, 27710-3000
Pediatric Specialty of VA /ID# 142831
Fairfax, Virginia, 22031
Cook Children's Med. Center /ID# 144474
Fort Worth, Texas, 76104
Connecticut Children's Medical Center - Hartford /ID# 137265
Hartford, Connecticut, 06106
Penn State Child Hosp.Hersh,PA /ID# 144476
Hershey, Pennsylvania, 17033
Texas Children's Hospital /ID# 148211
Houston, Texas, 77030-2608
Univ of Mississippi Med Ctr,US /ID# 137239
Jackson, Mississippi, 39216-4643
Nemours Children's Health System /ID# 148498
Jacksonville, Florida, 32207
Children's Hospital Los Angeles /ID# 141551
Los Angeles, California, 90027
Private practice: Dr. Shervin Rabizadeh /ID# 137269
Los Angeles, California, 90048
University of Miami /ID# 140893
Miami, Florida, 33136
Children's Hospital Wisconsin - Milwaukee Campus /ID# 137259
Milwaukee, Wisconsin, 53226
M Health Fairview University of Minnesota Medical Center - East Bank /ID# 137238
Minneapolis, Minnesota, 55455
University of South Alabama /ID# 137255
Mobile, Alabama, 36617
Goryeb Children's Hospital /ID# 144275
Morristown, New Jersey, 07960
Yale University School of Medicine /ID# 137257
New Haven, Connecticut, 06510
CCMC - Steven and Alexandra Cohen Children's Medical Center of New York /ID# 137266
New Hyde Park, New York, 11042-2057
Children's Hospital New Orleans /ID# 144477
New Orleans, Louisiana, 70118
Columbia Univ Medical Center /ID# 144440
New York, New York, 10032-3725
Columbia Univ Medical Center /ID# 144475
New York, New York, 10032-3725
Children's Hospital Oklahoma /ID# 144047
Oklahoma City, Oklahoma, 73104
Phoenix Children's Hospital /ID# 141336
Phoenix, Arizona, 85016-7710
Maine Medical Partners /ID# 147685
Portland, Maine, 04102
Mayo Clinic - Rochester /ID# 149245
Rochester, Minnesota, 55905-0001
Rady Children's Hospital San Diego /ID# 140883
San Diego, California, 92123
Univ California, San Francisco /ID# 141312
San Francisco, California, 94143-2204
Duplicate_Swedish Medical Center /ID# 137258
Seattle, Washington, 98104
Seattle Children's Hospital /ID# 140879
Seattle, Washington, 98105
Univ Med Ctr at Stony Brook /ID# 140913
Stony Brook, New York, 11794
SUNY Upstate Medical University /ID# 148437
Syracuse, New York, 13210
MultiCare Institute for Research & Innovation /ID# 152120
Tacoma, Washington, 98405
Duplicate_UMass Chan Medical School /ID# 148325
Worcester, Massachusetts, 01655
Spain23 sites
Complejo Hospitalario Universitario A Coruña /ID# 137235
A Coruña, A Coruna, 15006
Hospital Universitario Germans Trias i Pujol /ID# 139400
Badalona, Barcelona, 08916
OSI Ezkerraldea-Enkarterri-Cruces /ID# 141781
Barakaldo, Vizcaya, 48903
Hospital Universitario Vall d'Hebron /ID# 141778
Barcelona, 08035
Hospital Universitario Vall d'Hebron /ID# 146015
Barcelona, 08035
Hospital General de Granollers /ID# 140882
Barcelona, 08042
Hospital Clinico Universitario Virgen de la Arrixaca /ID# 138460
El Palmar, Murcia, 30120
Hospital Sant Joan de Deu /ID# 152059
Esplugues de Llobregat, Barcelona, 08950
Hospital Arquitecto Marcide - Complejo Hospitalario Universitario de Ferrol /ID# 138462
Ferrol, A Coruna, 15405
Hospital Universitario de Girona Doctor Josep Trueta /ID# 147572
Girona, 17007
Hospital Universitario Severo Ochoa /ID# 141545
Leganés, Madrid, 28911
Hospital Infantil Universitario Nino Jesus /ID# 165738
Madrid, 28009
Hospital Universitario 12 de Octubre /ID# 136998
Madrid, 28041
Hospital Universitario La Paz /ID# 161152
Madrid, 28046
Hospital Universitario Puerta de Hierro - Majadahonda /ID# 157872
Majadahonda, Madrid, 28222
Hospital Regional Universitario de Malaga /ID# 144289
Málaga, 29011
Hospital Universitario Central de Asturias /ID# 163053
Oviedo, Principality of Asturias, 33011
Hospital Universitari Son Espases /ID# 147446
Palma de Mallorca, Balearic Islands, 07120
Compl Hospital Univer de Vigo /ID# 136999
Pontevedra, 36312
Consorci Corporacio Sanitaria Parc Tauli Sabadell /ID# 149029
Sabadell, Barcelona, 08208
Complejo Hospitalario Universitario de Santiago (CHUS) /ID# 141667
Santiago de Compostela, A Coruna, 15706
Hospital Universitario Dr. Peset /ID# 159484
Valencia, 46017
Hospital Universitario y Politecnico La Fe /ID# 141847
Valencia, 46026
United Kingdom13 sites
NHS Grampian /ID# 131296
Aberdeen, AB15 6RE
Birmingham Women's and Children's NHS Foundation Trust /ID# 136631
Birmingham, B4 6NH
Duplicate_Cambridge University Hospitals NHS Foundation Trust /ID# 143779
Cambridge, CB2 0QQ
St Helier Hospital /ID# 150097
Carshalton, Surrey, SM5 1AA
University Hospital of Derby and Burton NHS Foundation Trust /ID# 131592
Derby, Derbyshire, DE22 3NE
Duplicate_NHS Greater Glasgow and Clyde /ID# 127436
Glasgow, Scotland, G12 0XH
Alder Hey Children's Hospital /ID# 138013
Liverpool, L12 2AP
Disc_Barts Health NHS Trust - The Royal London Hospital /ID# 128471
London, Greater London, E1 2ES
Manchester University NHS Foundation Trust /ID# 128476
Manchester, M9 2AA
Duplicate_The Newcastle Upon Tyne Hospitals NHS Foundation Trust /ID# 147438
Newcastle upon Tyne, NE7 7DN
Sheffield Children's Hospital NHS Foundation Trust /ID# 130370
Sheffield, England, S10 2TH
University Hospital Southampton NHS Foundation Trust /ID# 147538
Southampton, Hampshire, SO16 6YD
St George's University Hospitals NHS Foundation Trust /ID# 131590
Tooting, SW17 0QT
Germany10 sites
Universitaetsklinikum Aachen /ID# 126591
Aachen, North Rhine-Westphalia, 52074
Duplicate_Universitaetsklinikum Carl Gustav Carus an der TU Dresden /ID# 127696
Dresden, Saxony, 01307
Duplicate_Universitaetsklinikum Erlangen /ID# 137274
Erlangen, Bavaria, 91054
Froehlich Gemeinschaftspraxis /ID# 127975
Forchheim, 91301
Duplicate_Universitaetsklinikum Freiburg /ID# 130010
Freiburg im Breisgau, 79106
Kinderarztpraxis Neuhausen /ID# 144402
Munich, 80634
Duplicate_Universitaetsklinikum Muenster /ID# 148441
Munster, Lower Saxony, 48149
Christliches Kinderhospital Osnabrueck /ID# 136629
Osnabrück, Lower Saxony, 49074
Universitaetsklinikum Regensburg /ID# 137140
Regensburg, 93042
Universitaetsklinikum Ulm /ID# 148444
Ulm, Baden-Wurttemberg, 89081
Italy10 sites
Ospedale Maggiore Carlo Alberto Pizzardi /ID# 147347
Bologna, 40133
Duplicate_A.O.U. Policlinico G. Martino /ID# 141683
Messina, 98125
ASST Fatebenefratelli Sacco - Ospedale Fatebenefratelli e Oftalmico /ID# 144279
Milan, Milano, 20122
ASST Fatebenefratelli Sacco/Ospedale dei Bambini Vittore Buzzi /ID# 141679
Milan, 20154
Duplicate_Universita di Napoli Federico II /ID# 144280
Naples, 80131
Duplicate_POLICLINICO PAOLO GIACCONE /ID# 138410
Palermo, 90127
Azienda Ospedaliera Ospedali Riuniti Villa Sofia Cervello /ID# 152684
Palermo, 90146
Azienda Ospedaliero-Universitaria di Parma /ID# 147441
Parma, 43126
Azienda Usl Di Pescara - Presidio Ospedaliero Di Pescara /ID# 141307
Pescara, 65124
Azienda Ospedaliero-Universitaria Policlinico Umberto I /ID# 141962
Rome, Roma, 00161
Israel8 sites
Duplicate_Ha'Emek Medical Center /ID# 156316
Afula, 18341
Rambam Health Care Campus /ID# 162061
Haifa, 3109601
The Lady Davis Carmel Medical Center /ID# 151519
Haifa, 34362
Shaare Zedek Medical Center /ID# 144277
Jerusalem, Jerusalem, 91031
Schneider Children's Medical Center /ID# 152683
Petah Tikva, Central District, 4920235
Edmond And Lily Safra Children /ID# 148730
Ramat Gan, Tel Aviv, 5262100
Duplicate_Kaplan Medical Center /ID# 152945
Rehovot, Central District, 7661041
Yitzhak Shamir Medical Center /ID# 157182
Ẕerifin, Central District, 70300
Canada5 sites
Alberta Health Services /ID# 128717
Edmonton, Alberta, T6G 1C9
IWK Health Center /ID# 127912
Halifax, Nova Scotia, B3K 6R8
The Univ of Western Ontario /ID# 137962
London, Ontario, N6A 5K8
Hospital for Sick Children /ID# 127910
Toronto, Ontario, M5G 1X8
Duplicate_University of Manitoba / Health Scuience Centre / John Buhler Research /ID# 141310
Winnipeg, Manitoba, R3E 3P4
Czechia5 sites
Fakultní nemocnice Hradec Králové - Sokolská /ID# 128521
Hradec Králové, Hradec Kralove, 500 05
Fakultni nemocnice Olomouc /ID# 127437
Olomouc, 779 00
Fakultni Nemocnice Ostrava /ID# 127913
Ostrava, Ostrava-mesto, 708 52
Fakultni nemocnice Kralovske Vinohrady /ID# 127697
Prague, 100 34
Krajska zdravotni a.s. Masarykova nemocnice v Usti nad Labem o.z. /ID# 129829
Ústí nad Labem, 401 13
Greece5 sites
Agia Sofia Hospital /ID# 134349
Athens, Attica, 11527
General Hospital of Chest Diseases of Athens SOTIRIA /ID# 147690
Athens, Attica, 11527
Venizeleio General Hospital /ID# 147335
Heraklion, 71409
Iatriko Kentro Athinon /ID# 130639
Marousi, Attica, 15125
General Hospital of Thessaloniki Gennimatas /Id# 163658
Thessaloniki, 54635
Romania4 sites
Spitalul Clinic de Urgenta Pentru Copii Grigore Alexandrescu /Id# 130358
Bucharest, 011743
Spitalul Clinic de Urgenta pentru Copii- Pediatrie II-Nefrologie Pediatrica /ID# 131297
Cluj-Napoca, Cluj, 400177
Spitalul Clinic Judetean de Urgenta Targu Mures /ID# 137014
Târgu Mureş, 540136
Spitalul Clinic de Urgenta pentru Copii ?Louis Turcanu? /ID# 130251
Timișoara, Timiș County, 500063
Croatia2 sites
Zadar General Hospital /ID# 129830
Zadar, 23000
Klinicki bolnicki centar Sestre milosrdnice /ID# 128256
Zagreb, City of Zagreb, 10000
Estonia2 sites
Tallinn Children's Hospital /ID# 126974
Tallinn, Harju, 13419
Children's Clinic Of Tartu Uni /ID# 146017
Tartu, Tartu, 51014
France2 sites
Duplicate_Hôpital Pierre Wertheimer /ID# 128193
Bron, Rhone, 69677
AP-HP - Hopital Necker /ID# 147702
Paris, 75015
Lithuania2 sites
Hospital of Lithuanian University of Health Sciences Kaunas Clinics /ID# 127809
Kaunas, 50161
Vilnius University Hospital Santaros Klinikos /ID# 127810
Vilnius, 08661
Netherlands2 sites
Duplicate_Academisch Medisch Centrum /ID# 141843
Amsterdam, North Holland, 1105 AZ
Duplicate_Erasmus Medisch Centrum /ID# 141841
Rotterdam, South Holland, 3015 GD
Portugal2 sites
2CA-Braga, Hospital de Braga /ID# 138269
Braga, 4710-243
Unidade Local de Saude Sao Joao, EPE /ID# 138146
Porto, 4200-319
Puerto Rico2 sites
Ctr. Gastroenterologia Ped Oes /ID# 140875
Mayagüez, 00680
San Jorge Children Hospital /ID# 138067
San Juan, 00912-3310
Sweden2 sites
Karolinska University Hospital Solna /ID# 129045
Solna, Stockholm County, 171 64
Sodersjukhuset /ID# 152685
Stockholm, Stockholm County, 118 83
Bosnia and Herzegovina1 site
University Clinical Center Tuzla /ID# 130638
Tuzla, Tuzlanski, 75000
Denmark1 site
Kobenhavns Universitet - Hvidovre Hospital (HH) /ID# 146013
Hvidovre, Capital Region, 2650
About this study
Official title: A Long-Term Non-Interventional Postmarketing Study to Assess Safety and Effectiveness of Humira® (Adalimumab) in Pediatric Patients With Moderately to Severely Active Crohn's Disease (CD) - CAPE
This is a registry study to evaluate the long-term safety and effectiveness of adalimumab in pediatric patients with moderately to severely active CD who are treated as recommended in the local product label.
- Conditions
- Crohn's Disease
- Keywords
- Crohn's Disease, Registry, Adalimumab, Crohn's, Inflammatory Bowel Diseases, Gastrointestinal Diseases
- Medical subject headings
- Crohn Disease, Inflammatory Bowel Diseases, Gastrointestinal Diseases
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Immunosuppressant Therapy | Pediatric patients who are being prescribed and treated with immunosuppressant therapy | |
| Adalimumab (Humira) Treatment | Pediatric patients who are prescribed and treated with adalimumab |
What is being measured
The primary outcome is the main question the study is designed to answer.
Number of treatment-emergent AESI per 100 PYs of infections and malignancies
Measured: Up to 10 years
Percentage of subjects with SAEs
Measured: Up to 10 years
Number of treatment-emergent other AESI per 100 PYs
Measured: Up to 5 years
Percentage of subjects with other AESI
Percentages of subjects with AESIs other than infections and malignancies
Measured: Up to 5 years
Number of subjects with Adverse Events of Special Interest (AESI) of infections, malignancies, and pregnancies
Measured: Up to 10 years
Number of subjects with other AESI
Number of subjects with AESIs other than infections and malignancies
Measured: Up to 5 years
Number of treatment-emergent SAEs per 100 patient years (PYs)
Measured: Up to 10 years
Number of subjects with Serious Adverse Events (SAEs)
Measured: Up to 10 years
Percentage of subjects with AESI of infections, malignancies, and pregnancies
Measured: Up to 10 years
Secondary outcomes (5)
Short Pediatric Crohn's Disease Activity Index (sh-PCDAI)
Patient completed questionnaires
Measured: Up to 5 years
Short Quality of Life in Inflammatory Bowel Disease Questionnaire (SIBDQ)
Completed by the patients who are 18 years of age or older
Measured: Up to 5 years
Work Productivity and Activity Impairment (WPAI) questionnaire
Completed by caregiver up to the age of 17 years and completed by the patients of age 18 years or above.
Measured: Up to 5 years
Physician's Global Assessment of Disease Activity (PGA)
Completed by the physician
Measured: Up to 5 years
IMPACT III
Completed by patients ages 10 through 17 years old
Measured: Up to 5 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted5 May 2014 (estimated)
- Study start28 Aug 2014
- Primary completionNov 2030 (estimated)
- Study completionNov 2030 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Crohn's DiseaseStudies of the same condition, open and under way.
- More trials run by AbbVieThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 1,446 participants (actual)
Sponsor and investigators
- Lead sponsor
- AbbVie
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- ABBVIE INC., Study director, AbbVie
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02130362
- Sponsor's protocol ID
- P11-292
- Acronym
- CAPE
- Status last verified
- Jul 2025
- First submitted
- 1 May 2014
- Last updated
- 16 Jul 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 16 Jul 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Long-Term Non-Interventional Postmarketing Study to Assess Safety and Effectiveness of Humira® (Adalimumab) in Pediatric Patients With Moderately to Severely Active Crohn's Disease (CD) - CAPE
- ClinicalTrials.gov ID
- NCT02130362
- Acronym / sponsor ID
- CAPE / P11-292
- Conditions
- Crohn's Disease
- Keywords
- Crohn's Disease, Registry, Adalimumab, Crohn's, Inflammatory Bowel Diseases, Gastrointestinal Diseases
- Study type
- Observational
- Recruitment status
- Active, not recruiting
- Enrolment
- 1,446 participants (actual)
- Lead sponsor
- AbbVieIndustry (pharma, biotech, devices)
- Study start
- 28 Aug 2014 (actual)
- Primary completion
- Nov 2030 (estimated)
- Study completion
- Nov 2030 (estimated)
- First posted
- 5 May 2014 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This is a registry study to evaluate the long-term safety and effectiveness of adalimumab in pediatric patients with moderately to severely active CD who are treated as recommended in the local product label.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Immunosuppressant Therapy | – | –Pediatric patients who are being prescribed and treated with immunosuppressant therapy |
| Adalimumab (Humira) Treatment | – | –Pediatric patients who are prescribed and treated with adalimumab |
Who may qualify
- Ages
- 6 to 17 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child
- Study population
- Pediatric patients with moderately to severely active Crohn's Disease (CD) who have been prescribed HUMIRA according to the local label and pediatric patients being prescribed and treated with IMM (azathioprine, 6-mercaptopurine, or methotrexate). Patients being prescribed and treated with immunosuppressant therapy with no concurrent biologic use will be enrolled as a reference group.
Key inclusion criteria (3 listed)
- For a patient enrolling into the HUMIRA treatment group; A pediatric patient between the ages of 6 and 17 years inclusive at the time of enrollment, diagnosed with moderately to severely active CD who has been prescribed Humira therapy according to the routine clinical practice.
- For a patient enrolling into the immunosuppressant therapy treatment group; A pediatric patient between the ages of 6 and 17 years inclusive at the time of enrollment, diagnosed with moderately to severely active CD who has been prescribed azathioprine, 6-mercaptopurine or methotrexate.
- Parent or guardian; or patient (if 18 years of age or older at enrollment and rolling over from an AbbVie-sponsored investigational Pediatric CD investigation trial) has voluntarily signed and dated an Authorization for Use/Disclosure of Data (AUDD)/informed consent form (ICF) after the nature of the registry has been explained and the patient, patient's parent or legal guardian has had the opportunity to ask questions.
Key exclusion criteria (2 listed)
- Patients should not be enrolled into the registry if they are currently being treated with any investigational agents or are receiving any investigational procedures.
- Patients should not be enrolled into the immunosuppressant therapy treatment group if they require ongoing treatment with approved biologic agents including HUMIRA.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Number of treatment-emergent AESI per 100 PYs of infections and malignancies
Time frame: Up to 10 years
Percentage of subjects with SAEs
Time frame: Up to 10 years
Number of treatment-emergent other AESI per 100 PYs
Time frame: Up to 5 years
Percentage of subjects with other AESI
Time frame: Up to 5 years
Percentages of subjects with AESIs other than infections and malignancies
Number of subjects with Adverse Events of Special Interest (AESI) of infections, malignancies, and pregnancies
Time frame: Up to 10 years
Number of subjects with other AESI
Time frame: Up to 5 years
Number of subjects with AESIs other than infections and malignancies
Number of treatment-emergent SAEs per 100 patient years (PYs)
Time frame: Up to 10 years
Number of subjects with Serious Adverse Events (SAEs)
Time frame: Up to 10 years
Percentage of subjects with AESI of infections, malignancies, and pregnancies
Time frame: Up to 10 years
5 secondary outcomes
Short Pediatric Crohn's Disease Activity Index (sh-PCDAI)
Time frame: Up to 5 years
Short Quality of Life in Inflammatory Bowel Disease Questionnaire (SIBDQ)
Time frame: Up to 5 years
Work Productivity and Activity Impairment (WPAI) questionnaire
Time frame: Up to 5 years
Physician's Global Assessment of Disease Activity (PGA)
Time frame: Up to 5 years
IMPACT III
Time frame: Up to 5 years
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 16 Jul 2025.
- Related InfoLink provided by the sponsor.
- Individual participant dataSharing planned: Undecided
Related trials for Crohn's Disease
RecruitingPhase 4
PATHFINDER: Evaluating the Optimal First-Line Treatment Strategy for Moderate-to-Severely Active Ileal-dominant Crohn's Disease
Crohn Disease
RecruitingPhase 3
A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease
Moderately to Severely Active Crohns Disease
RecruitingPhase 4
Open-label Single-arm Study to Assess the Efficacy of Mirikizumab in Patients With Inflammatory Strictures Due to CD
Crohn Disease
RecruitingObservational study
Longitudinal Immunophenotyping of Patients With Inflammatory Bowel Disease
Inflammatory Bowel Disease, Crohn's Disease
Not yet recruiting
Online Pain Education for Crohn's Disease and Ulcerative Colitis
Crohn's Disease, Ulcerative Colitis (UC)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
ABBVIE INC. study director
AbbVie
148 sites in 22 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Crohn's Disease, run by AbbVie at 148 sites in 22 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 16 Jul 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 148 sites in United States, Spain, United Kingdom, Germany, Italy and 17 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Number of treatment-emergent AESI per 100 PYs of infections and malignancies (time frame: Up to 10 years). The study lists 9 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 16 Jul 2025; AzTrials last refreshed its copy on 27 Oct 2026.